×
About 1,660 results

ALLMedicine™ Hepatorenal Syndrome Center

Research & Reviews  507 results

Hepatorenal Syndrome and Other Post-Liver Transplantation Complications: Case Studies a...
https://doi.org/10.1016/j.transproceed.2022.03.036
Transplantation Proceedings; Januszko-Giergielewicz B, Kobryń A et. al.

Jun 28th, 2022 - Hepatorenal syndrome (HRS) was originally defined as a renal dysfunction caused by a decreased renal perfusion due to hemodynamic disturbances in the arterial circulation and an excessive activity of endogenous vasoactive systems in the course of ...

Continuous Renal Replacement Therapy with Regional Citrate Anticoagulation in Children ...
https://doi.org/10.1093/tropej/fmac048
Journal of Tropical Pediatrics; Botan E, Durak A et. al.

Jun 24th, 2022 - Regional citrate anticoagulation (RCA) is an option but citrate accumulation is risk and it is a giving up cause for this situation. This retrospective study was conducted in the pediatric intensive care unit (PICU) between May 2019 and April 2021...

Negative pressure wound therapy for prolonged surgical wound healing after brachiobasil...
https://doi.org/10.1177/11297298221106102
The Journal of Vascular Access; Takai K, Saeki M et. al.

Jun 17th, 2022 - A 54-year-old male patient diagnosed with hepatorenal syndrome caused by decompensated alcoholic cirrhosis was referred for arteriovenous fistula (AVF) creation after initiation of hemodialysis. A brachiobasilic arteriovenous fistula (BBAVF) was c...

Angiotensin 2 for AKI After OLT
https://clinicaltrials.gov/ct2/show/NCT04592744

Jun 15th, 2022 - Acute kidney injury is a common perioperative complication following liver transplantation with an incidence of approximately 55%. Due to the complex physiologic derangements present in cirrhotic patients, multiple etiologies and processes may con...

The Effect of Artificial Liver Support System on Prognosis of HBV-Derived Hepatorenal S...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177308
Disease Markers; Sheng X, Zhou J et. al.

Jun 14th, 2022 - Hepatorenal syndrome (HRS) could occur when patients get decompensated liver cirrhosis. Meanwhile, hepatitis B virus (HBV) infection raises the risk of mortality of the end-stage liver diseases. As the artificial liver support system (ALSS) has be...

see more →

Guidelines  1 results

Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and...
https://doi.org/10.1002/hep.31884
Hepatology (Baltimore, Md.); Biggins SW, Angeli P et. al.

May 5th, 2021 - Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.|2021|Biggins SW,Angeli P,Garcia-Tsao G,Ginès P,Ling S...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  95 results

Angiotensin 2 for AKI After OLT
https://clinicaltrials.gov/ct2/show/NCT04592744

Jun 15th, 2022 - Acute kidney injury is a common perioperative complication following liver transplantation with an incidence of approximately 55%. Due to the complex physiologic derangements present in cirrhotic patients, multiple etiologies and processes may con...

A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
https://clinicaltrials.gov/ct2/show/NCT04112199

Jun 6th, 2022 - Terlipressin has been shown to reduce portal hypertension, improve renal function and induce natriuresis in cirrhotic patients with ascites without hepatorenal syndrome (HRS). It is approved in Europe for the treatment of bleeding esophageal varic...

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
https://clinicaltrials.gov/ct2/show/NCT04541173

May 31st, 2022 - Subjects will be randomized to Y-90 TARE alone (Arm A) or Y-90 TARE followed by the combination of atezolizumab and bevacizumab (Arm B). The first 10 subjects randomized to Arm B (Y-90 TARE + bevacizumab + atezolizumab) will be assessed for safety...

Non-invasive Evaluation of the Predictive Value of CEUS and SWE in ACLF, Renal Failure and Hepatorenal Syndrome
https://clinicaltrials.gov/ct2/show/NCT04446858

May 18th, 2022 - NECTAR consists of patients with ACLF and renal failure with and without receiving transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Internal Medicine I, University of Bonn, Germany and receiving a structured routine evalua...

HRS-AKI Treatment With TIPS in Patients With Cirrhosis
https://clinicaltrials.gov/ct2/show/NCT05346393

May 2nd, 2022 - Cirrhosis is a major cause of global health burden worldwide. Acute kidney injury (AKI) occurs in 20% of hospitalized patients with cirrhosis. Acute kidney injury is a relatively new definition of renal failure which takes into account the dynamic...

see more →

News  60 results

ARPA-H Under Bipartisan Fire; BA.2 Still a Concern; COVID's Toll on Long-Term Care
https://www.medpagetoday.com/infectiousdisease/covid19/97320

Feb 23rd, 2022 - Note that some links may require registration or subscription. Merck's anti-viral pill molnupiravir is of more limited use in COVID-19 patients at risk for severe disease as compared with Pfizer's nirmatrelvir-ritonavir (Paxlovid), say experts. (N...

Terlipressin Shows Benefit in Hepatorenal Syndrome but Risks Spark Concern
https://www.medscape.com/viewarticle/946833

Mar 4th, 2021 - NEW YORK (Reuters Health) - Details of the phase-3 CONFIRM trial show the vasopressin analog terlipressin can reverse the effects of type 1 hepatorenal syndrome (HRS-1), although not without potentially serious side effects. The study, published i...

Axitinib/Octreotide Combo Fails to Improve PFS in Pancreatic NETs
https://www.onclive.com/view/axitinib-octreotide-combo-fails-to-improve-pfs-in-pancreatic-nets

Jan 17th, 2021 - Axitinib (Inlyta) plus octreotide LAR failed to demonstrate a significant improvement in progression-free survival (PFS) compared with placebo plus octreotide LAR in patients with advanced G1-2 extra-pancreatic neuroendocrine tumors (NETs), accord...

FDA Accepts Cabozantinib Application for Advanced HCC
https://www.onclive.com/view/fda-accepts-cabozantinib-application-for-advanced-hcc

Dec 4th, 2020 - Gisela Schwab, MD The FDA has accepted a supplemental new drug application (sNDA) for cabozantinib (Cabometyx) as a treatment for patients with previously-treated advanced hepatocellular carcinoma (HCC), according to a statement from the company ...

Cabozantinib Approved in Japan for Advanced Hepatocellular Carcinoma
https://www.onclive.com/view/cabozantinib-approved-in-japan-for-advanced-hepatocellular-carcinoma

Nov 30th, 2020 - The Japanese Ministry of Health, Labor, and Welfare has approved cabozantinib (Cabometyx) for the treatment of patients with unresectable hepatocellular carcinoma (HCC) that has progressed on prior systemic therapy.1 The approval is based on resu...

see more →